Assessing Regenxbio: Insights From 5 Financial Analysts
Portfolio Pulse from Benzinga Insights
Regenxbio (NASDAQ:RGNX) has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target has decreased by 4% to $40.8. Analysts have adjusted their ratings and price targets based on recent developments, reflecting their perceptions of the company's market position. Regenxbio has shown significant revenue growth but faces challenges with its net margin and return on assets.
September 04, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regenxbio has received a mix of bullish and somewhat bullish ratings from analysts, with a decrease in the average 12-month price target to $40.8. The company's revenue growth is strong, but it faces challenges with its net margin and return on assets.
The mixed analyst ratings and the decrease in the average price target suggest a neutral short-term impact on RGNX's stock price. While the company shows strong revenue growth, its financial metrics like net margin and ROA indicate potential challenges, balancing the overall outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100